The primary objective of this study is to demonstrate the safety and performance of the PFx Closure System when utilized for patients with PFOs suffering from cryptogenic stroke, transient ischemic attack, migraine or decompression illness.
Patent Foramen Ovale has been implicated in the etiology of paradoxical embolism, cryptogenic stroke, transient ischemic attack, and right to left gas embolism in severe decompression illness. An association between patent foramen ovale and severe migraine headaches has also been reported. Several implantable devices are being used for percutaneous closure of patent foramen ovale; this study uses a non-implantable system to safely effect closure with the application of radiofrequency energy.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
AZ Middleheim Hospital
Antwerp, Belgium
Institut Hospitalier Jacques Carter
Massy, France
Bichat Hospital
Paris, France
Cardiovascular Center Frankfurt Sankt katharinen
Frankfurt, Germany
PFO closure 6 months post procedure
Time frame: 6 months
PFO closure at 30 days and 12 months post procedure
Time frame: 30 days, 12 months
AE event rates for all subjects
Time frame: 30 days, 6 and 12 months
Migraine severity
Time frame: 6 and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.